Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Updates on PsA: Insights into the Latest Psoriatic Arthritis Treatments & Research

Jason Liebowitz, MD, FACR  |  Issue: October 2022  |  August 11, 2022

BALTIMORE—Psoriatic arthritis (PsA) was once dismissed by some as “rheumatoid arthritis with rash.” Despite that attitude, the understanding of PsA, its diagnosis and treatment, and management of comorbidities have come a long way.

At the 18th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases, held May 13–14 at the Johns Hopkins School of Medicine, Baltimore, Ana-Maria Orbai, MD, MHS, associate professor of medicine and director of the Psoriatic Arthritis Program at the Johns Hopkins School of Medicine, began the session by discussing the latest medications that have entered the PsA armamentarium.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Medication Overview

Risankizumab is an anti-interleukin (IL) 23 monoclonal IgG1 antibody. In January, the U.S. Food & Drug Administration (FDA) approved risankizumab to treat adults with PsA. Unlike some other medications approved to treat PsA and psoriasis, the treatment dose is the same for both conditions. In terms of safety profile, some of the main potential side effects include upper respiratory tract infections, headache, fatigue, injection-site reactions and tinea infections.

Dr. Orbai

Dr. Orbai

The ACR20 and ACR50 response rates to risankizumab are good for the treatment of patients naive to biologics, as well as for patients with prior biologic use, noted Dr. Orbai.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the KEEPsAKE 1 trial, 964 patients with active PsA who were intolerant to or for whom one or more conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) proved inadequate were randomized to receive 150 mg of risankizumab or placebo at weeks 0, 4 and 16. With a primary end point of an ACR20 response at week 24, the study found a significantly greater proportion of patients receiving risankizumab achieved that end point (57.3% vs. 33.5% for placebo; P<0.001).1 (Note: An ACR20 response is defined as a 20% improvement in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure, visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein level.)

In December 2021, the FDA approved upadacitinib, a Janus kinase (JAK) inhibitor, for the treatment of patients who have had inadequate response to, or are intolerant of, one or more tumor necrosis factor-α (TNF) inhibitors.

Dr. Orbai addressed the FDA boxed warning for JAK inhibitors. This warning notes an increased risk for serious infections, mortality, malignancy, major adverse cardiac events and thrombosis. However, similar to risankizumab, upadacitinib proved beneficial in treating patients naive to biologics or with prior biologic use. Also, data indicate that upadacitinib may slow the radiographic progression of PsA, which is important to prevent joint deformities and impaired function in patients.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsPsoriatic Arthritis Tagged with:Annual Advances in the Diagnosis and Treatment of the Rheumatic DiseasesPsoriatic Arthritisrisankizumabupadacitinib

Related Articles

    The Heterogeneity of Psoriatic Arthritis

    November 21, 2023

    SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.

    Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

    December 1, 2022

    PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

    Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

    September 20, 2018

    A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

    FDA Approves Risankizumab-rzaa for PsA

    April 20, 2022

    Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences